上海昊海生物科技股份有限公司 06826Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name上海昊海生物科技股份有限公司
Stock Code06826
Company Full Name上海昊海生物科技股份有限公司
Industry醫療保健
Principal Activities主要於中國從事制造及銷售醫用透明質酸及生物制劑、生物工程及藥品研發,以及提供相關服務。
Listing Date2015-04-30
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市長寧區虹橋路1386號文廣大廈23樓
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.3healthcare.com/
Share Registrar香港中央證券登記有限公司
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data
// Offering Information //
Prospectus Date2015-04-20
Offer PriceHK$ 59.00 / shares
Total Funds RaisedHK$ 1,180,000,000
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 54.0
First Day Change-1.01%
First Day Volume18649000.0
First Day Turnover1065410000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約25%或約563百萬港元,將用于建設上海利康瑞的新生產線,包括動物源纖維蛋白封閉劑產品及醫用生物材料的新生產設施,以應付對產品不斷增長的需求; 2、約25%或約563百萬港元,將用于選擇性收購專注于我們目標治療領域內具高增長潛能產品及對我們現有產品組合具互補性產品的合適生物醫藥或醫用生物材料公司或資產。截至最后實際可行日期,我們尚未物色到任何可予收購的目標; 3、約18%的所得款項凈額,或約405百萬港元,將用于購買新生產設備,以及翻新及改造昊海生物設施; 4、約13%或約293百萬港元,將用于資助在研產品(包括溫敏性幾丁糖產品及新一代交聯透明質酸鈉產品)的研發活動及臨床應用; 5、約9%或約203百萬港元,將用于招聘更多營銷及銷售人員以擴大我們的銷售及營銷網絡,及將我們成功開發的在研產品進行商業投產,以及提升營銷及促銷活動水平; 6、約10%或約225百萬港元,將用作營運資金及一般企業用途。
// Underwriting Syndicate //
独家保荐人 (1)
瑞银证券香港有限公司
整体协调人 (1)
瑞银证券香港有限公司
联席账簿管理人 (3)
瑞银证券香港有限公司 招银国际融资有限公司 建银国际金融有限公司
联席牵头经办人 (3)
瑞银证券香港有限公司 招银国际融资有限公司 建银国际金融有限公司
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Dragon Billion China Master Fund 193,697,000 HKD 2.05% 6 months 2015-10-30
2 方圆投资管理(香港)有限公司 232,460,000 HKD 2.46% 6 months 2015-10-30
// Directors & Management //
Chairman侯永泰
Company Secretary田敏;黎映彤
No director data available.
// Major Shareholders //
Major Shareholders & Holdings蔣偉(45.34%)
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics